GURUFOCUS.COM » STOCK LIST » Asia » China » SZSE » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » 3-Year ROIIC %
Switch to:

China National Accord Medicines (SZSE:000028) 3-Year ROIIC %

: 5.60% (As of Dec. 2022)
View and export this data going back to 1993. Start your Free Trial

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. China National Accord Medicines's 3-Year ROIIC % for the quarter that ended in Dec. 2022 was 5.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for China National Accord Medicines's 3-Year ROIIC % or its related term are showing as below:

SZSE:000028's 3-Year ROIIC % is ranked worse than
53.66% of 82 companies
in the Medical Distribution industry
Industry Median: 6.41 vs SZSE:000028: 5.60

China National Accord Medicines 3-Year ROIIC % Historical Data

The historical data trend for China National Accord Medicines's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year ROIIC %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.14 8.65 7.04 5.14 5.60

China National Accord Medicines Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
3-Year ROIIC % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 5.60 -

Competitive Comparison

For the Medical Distribution subindustry, China National Accord Medicines's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

China National Accord Medicines 3-Year ROIIC % Distribution

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's 3-Year ROIIC % falls in comparison to its industry or sector. The grey bar indicates the 3-Year ROIIC %'s extreme value range as defined by GuruFocus.



China National Accord Medicines 3-Year ROIIC % Calculation

China National Accord Medicines's 3-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( 1849.399502 (Dec. 2022) - 1410.420336 (Dec. 2019) )/( 18391.973 (Dec. 2022) - 10548.064 (Dec. 2019) )
=438.979166/7843.909
=5.60%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


China National Accord Medicines  (SZSE:000028) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


China National Accord Medicines 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

China National Accord Medicines logo
Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines